Impact of ADCY9 Genotype on Response to Anacetrapib

Supplemental Digital Content is available in the text.

[1]  S. Lévesque,et al.  ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein) , 2018, Circulation.

[2]  A. Lincoff,et al.  ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study , 2018, JAMA cardiology.

[3]  D. Rader,et al.  Trials and Tribulations of CETP Inhibitors. , 2018, Circulation research.

[4]  F. Chen,et al.  Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .

[5]  C. Granger,et al.  Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease , 2017, The New England journal of medicine.

[6]  M. Landray,et al.  Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics , 2017, American heart journal.

[7]  J. Tardif,et al.  CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib. , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[8]  P. Amouyel,et al.  Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease , 2015, Cardiovascular Drugs and Therapy.

[9]  G. Valen,et al.  Higher TNFα responses in young males compared to females are associated with attenuation of monocyte adenylyl cyclase expression. , 2015, Human immunology.

[10]  J. Tardif,et al.  Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib , 2015, Circulation. Cardiovascular genetics.

[11]  M. Peters,et al.  Systematic identification of trans eQTLs as putative drivers of known disease associations , 2013, Nature Genetics.

[12]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[13]  W. Losert,et al.  mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. , 2010, Developmental cell.

[14]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.